Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Sees Significant Growth in Short Interest

by · The Markets Daily

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) was the target of a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 81,750 shares, an increase of 58.7% from the September 15th total of 51,519 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 438,330 shares, the short-interest ratio is presently 0.2 days.

Chugai Pharmaceutical Price Performance

OTCMKTS CHGCY opened at $19.97 on Friday. Chugai Pharmaceutical has a 1 year low of $18.33 and a 1 year high of $34.84. The company has a market cap of $65.73 billion, a price-to-earnings ratio of 20.91 and a beta of 0.60. The stock’s fifty day moving average price is $20.94 and its 200 day moving average price is $23.17.

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last posted its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. The company had revenue of $2.14 billion during the quarter, compared to analyst estimates of $2.38 billion. Research analysts expect that Chugai Pharmaceutical will post 0.96 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on CHGCY shares. UBS Group downgraded Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Nomura raised Chugai Pharmaceutical to a “hold” rating in a research note on Tuesday, September 1st. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy”.

Check Out Our Latest Stock Analysis on CHGCY

About Chugai Pharmaceutical

(Get Free Report)

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization.

Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer.

Further Reading